NEW YORK, Nov. 21, 2022 /PRNewswire/ — Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that four abstracts highlighting CFI-402257 and CFI-400945, the Company’s potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022┬áSan Antonio Breast Cancer Symposium (SABCS) being held from┬áDecember 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.┬á
“We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation,” said Dr. Michael Tusche, Treadwell co-CEO. “We look forward to additional data from these studies, as we further characterize the utility of our agents in various breast cancer settings.”
Information on the four abstracts:
Abstract Title: An Update to a Phase I Trial of CFI-402257, an oral TTK Inhibitor, in Patients with Advanced Solid Tumors with HER2-Negative Breast Cancer Expansion Cohorts
Poster ID:        P6-10-13
Session:┬á ┬á ┬á ┬á ┬á Treatment: Therapeutic Strategies – Novel Targets and Targeted Agents
Date:                Friday, December 9, 2022
Time:               7:00 am CT
Abstract Title: CCTG IND.236: A Phase 1b Trial of Combined CFI-402257 and Weekly Paclitaxel in Patients with HER2 Negative (HER2-) Advanced Breast Cancer (aBC)
Poster ID:        P3-07-10
Session:┬á ┬á ┬á ┬á ┬á Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies
Date:                Wednesday, December 7, 2022
Time:                5:00 pm CT
Abstract Title: CCTG IND.237: A phase II study of CFI-400945 in patients with advanced/metastatic HER2-negative breast cancer
Poster ID:        P3-07-14
Date:                Wednesday, December 7, 2022
Time:                5:00 pm CT
Abstract Title: CCTG IND.239: A Phase 2 Study of Combined CFI-400945 and Durvalumab in Patients with Advanced Triple Negative Breast Cancer (aTNBC)
Poster ID:        P3-07-18
Date:                Wednesday, December 7, 2022
Time:                5:00 pm CT
About Treadwell Therapeutics
Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.┬á The Company’s internally developed clinical pipeline includes CFI-400945, CFI-402257 and CFI-402411 (HPK1 inhibitor).┬á The company is also advancing a pre-clinical pipeline of first-in-class antibody and TCR-based cell therapy assets.┬á For more information, please visit www.treadwelltx.com.
Contact
ir@treadwelltx.com
SOURCE Treadwell Therapeutics